Halozyme Therapeutics (HALO) Free Cash Flow (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Free Cash Flow data on file, last reported at $176.3 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at $176.3 million, up 14.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $673.3 million (up 36.24% YoY), and the FY2025 annual result was $650.7 million, up 38.92% from the prior year.
• Free Cash Flow retreated to $176.3 million in Q1 2026 per HALO's latest filing, from $223.7 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $223.7 million in Q4 2025 and troughed at $39.3 million in Q2 2022.
• A 5-year average of $112.0 million and a median of $97.7 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow plunged 43.4% in 2022, then jumped 100.26% in 2024.
• A 5-year view of Free Cash Flow shows it stood at $80.1 million in 2022, then grew by 9.34% to $87.6 million in 2023, then surged by 100.26% to $175.4 million in 2024, then gained by 27.51% to $223.7 million in 2025, then fell by 21.16% to $176.3 million in 2026.
• Business Quant data shows HALO's Free Cash Flow at $176.3 million in Q1 2026, $223.7 million in Q4 2025, and $175.6 million in Q3 2025.